证券代码：688336 证券简称：三生国健 公告编号：2025-035 三生国健药业（上海）股份有限公司 第五届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 三生国健药业（上海）股份有限公司（以下简称"公司"）第五 届监事会第六次会议于 2025 年 6 月 25 日以现场结合通讯方式召开。 经全体监事同意，一致豁免本次会议通知的期限要求，并已在会议上 就豁免通知时限的相关情况做出说明，会议由监事会主席曹虹女士主 持，会议应到监事 3 名，实到监事 3 名。本次会议的召集与召开程序、 出席会议人员资格及议事和表决程序符合《中华人民共和国公司法》 和《三生国健药业（上海）股份有限公司章程》（以下简称"《公司 章程》"）的有关规定。 监事会对本次限制性股票授予价格调整事项进行了核查，认为董 事会根据公司 2024 年第二次临时股东大会授权对本激励计划的授予 价格进行调整的事由恰当、充分，审议程序合法合规，符合《上市公 司股权激励管理办法》（以下简称"《管理办法》"）等有关法 ...

Group 1 - The first "doubling fund" in the public fund market for 2025 is the Huatai-PineBridge Hong Kong Advantage Selection A, which has achieved a 99.5% year-to-date return as of June 13, 2025, leading the entire market [1][2] - Among the top 10 funds for year-to-date returns in 2025, 8 are heavily invested in pharmaceutical companies, particularly in the innovative drug sector [1][2] - The innovative drug sector has seen significant growth, with the Wind Innovative Drug Concept Index rising over 25% and the Hang Seng Innovative Drug Index increasing over 53% since April 9, 2025 [2][3] Group 2 - Notable stocks in the innovative drug sector have experienced substantial price increases, with Shuyou Pharmaceutical leading at a 478.84% increase, followed by Sanofi Health at 129.81% [3][4] - The top-performing funds have a high concentration of investments in innovative drug companies, with the most frequently held stock being Kelong Biotechnology-B, which has also doubled in price [4][5] - Fund managers of the top-performing funds are predominantly new faces, with half of them having less than two years of investment experience [5][6] Group 3 - Zhang Wei, the manager of Huatai-PineBridge Hong Kong Advantage Selection A, has maintained a strong focus on the pharmaceutical sector, with the fund's top holdings consistently being in the biopharmaceutical industry [7][8] - The fund has shown resilience despite previous years of losses, with a significant recovery in 2025 attributed to the performance of its long-held innovative drug stocks [9][10] - Zhang Wei's investment strategy emphasizes long-term perspectives and stability in holdings, focusing on companies with global competitiveness and growth potential in the pharmaceutical and biotech sectors [10][11] Group 4 - The performance disparity among active equity funds in 2025 is notable, with 12 funds experiencing declines of over 20%, including several managed by Jin Zicai [13][14] - Jin Zicai's aggressive investment style has led to high turnover rates and concentrated positions, which can result in significant volatility [15][16] - The overall market sentiment towards innovative drugs remains positive, with expectations for continued growth driven by domestic medical demand recovery and supportive policies [10][11]

Core Viewpoint - The article discusses the surge in out-licensing deals among innovative pharmaceutical companies in China, highlighting the positive impact on stock prices and market valuations as these companies enter a revenue-generating phase after years of R&D investment [1][4]. Group 1: Out-Licensing Transactions - Significant out-licensing deals have recently occurred, including a record $1.25 billion upfront payment for SSGJ-707 from 3SBio to Pfizer, and a potential $11.1 billion revenue for BioNTech from a collaboration with Bristol-Myers Squibb on BNT327 [3][4]. - Since the beginning of 2025, the total value of out-licensing transactions from China has exceeded $50 billion, accounting for 44% of the global total, with upfront payments around $2.5 billion, representing 23% of global upfront payments [4][5]. Group 2: Stock Market Impact - The stock prices of innovative pharmaceutical companies have seen significant increases due to successful out-licensing deals, with 25 out of 59 biotech companies in Hong Kong doubling their stock prices this year [2][6]. - 3SBio's stock rose by 32.28% on the day of announcing its out-licensing deal, and another company, CSPC Pharmaceutical Group, saw a 20% increase following a licensing announcement [6][7]. Group 3: Industry Dynamics - The article notes that the long development cycles and high costs associated with innovative drug development lead many companies to seek out-licensing as a strategy to generate immediate revenue [9][11]. - There is a concern regarding the potential loss of pricing power for Chinese companies if they sell their pipelines too early, which could lead to higher future costs to re-enter the market [12][13].

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a significant surge in external licensing deals, leading to substantial stock price increases for many companies in the industry [2][5][8]. Group 1: Stock Performance - Among 59 Hong Kong-listed biotech companies, 25 have seen their stock prices double this year [3][6]. - The stock prices of several companies have surged due to successful licensing deals, with notable increases such as 32.28% on the day of announcement for Sanofi [6]. - The top five performing companies in the 18A sector have seen stock price increases of 538.46%, 386.56%, 319.69%, 267.8%, and 233.33% respectively [6]. Group 2: Licensing Deals - Significant licensing transactions have occurred, including a $12.5 billion upfront payment for a drug by Sanofi, setting a record for Chinese innovative drugs [4]. - Another deal between Bristol-Myers Squibb and BioNTech could yield up to $11.1 billion in revenue for BioNTech [4]. - China accounted for 44% of the global total licensing transaction value this year, with over $50 billion in deals [5]. Group 3: Industry Dynamics - The innovative drug industry is characterized by long development cycles, high costs, and low success rates, with an average cost of $2.3 billion for oncology drugs [8]. - The demand for innovative drugs is increasing as major pharmaceutical companies face patent expirations, creating a market opportunity for Chinese firms [8]. - Chinese companies are leading in various therapeutic areas, with more pipelines than the U.S. [9]. Group 4: Strategic Considerations - The trend of external licensing raises questions about the long-term implications for Chinese companies, particularly regarding their ability to commercialize products independently [10][11]. - Concerns exist about the potential loss of pricing power and market control if companies sell their pipelines too early [10][11]. - The industry is viewed as a trial-and-error game, where Chinese firms have a competitive edge in the efficiency of their trial processes [9].

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - Baiyunshan received drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration, indicating its entry into the erectile dysfunction treatment market [1] - Huayin Power plans to invest approximately 1.398 billion yuan in three renewable energy projects with a total installed capacity of 230 MW [2] - GAC Group reported a 24.8% year-on-year decline in May automobile sales, with total sales of 117,700 units [3] Group 2 - Honghui Fruits and Vegetables announced a potential change in control due to share transfer negotiations, leading to a temporary suspension of its stock and convertible bonds [4] - Fuyuan Pharmaceutical's subsidiary received a drug registration certificate for Bromhexine Hydrochloride oral solution, aimed at treating respiratory diseases [5][6] - Jianghan New Materials plans to repurchase shares worth 200 million to 400 million yuan, with a maximum price of 30 yuan per share [7][8] Group 3 - Sinan Navigation received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau due to multiple issues in its 2024 annual report [9][10] - Hesheng Co. received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [11] - Daqin Railway reported a 1.85% year-on-year decrease in cargo transportation volume in May, totaling 32.96 million tons [13] Group 4 - Ningbo Construction's subsidiary won a design and construction project with a bid of 787 million yuan [14] - Yuehongyuan A announced the termination of a major asset restructuring plan due to failure to reach an agreement on key terms [15][16] - Mingyang Smart Energy reached a 190 million yuan repurchase agreement with Haiji New Energy [18] Group 5 - CNE Group's subsidiary plans to reduce registered capital from 430 million yuan to 330 million yuan [19] - ST Baili received an administrative penalty for failing to disclose non-operating fund occupation matters, resulting in a fine of 4 million yuan [21] - Baichuan Co. completed the repurchase of a 7.14% stake in its subsidiary for 50 million yuan [22] Group 6 - Dongrui Co. reported May sales of 155,400 pigs, generating revenue of 203 million yuan, a decrease of 8.77% month-on-month [25][26] - Pengding Holdings reported a 22.43% year-on-year increase in May consolidated revenue, totaling 2.598 billion yuan [27] - Dabeinong reported May sales of 727,600 pigs, with total revenue of 1.248 billion yuan [28] Group 7 - Lihua Co. reported a 4.77% year-on-year decrease in May chicken sales revenue, totaling 1.118 billion yuan [29][30] - Jindan Technology plans to use up to 300 million yuan of idle funds for entrusted wealth management [31] - Youxunda won a project from the State Grid worth approximately 176 million yuan [33][34] Group 8 - Shenglan Co. received approval for its convertible bond issuance from the Shenzhen Stock Exchange [35][36] - Jingfang Technology's shareholder plans to reduce holdings by up to 2% of the company's shares [37] - Shiji Information's subsidiary signed a significant contract with Marriott for cloud services [39] Group 9 - Northeast Securities' subsidiary plans to terminate its listing on the New Third Board [40] - Yaji International's supervisor is under investigation for insider trading [42][43] - Yian Technology signed a strategic cooperation framework agreement with Shenzhen Hive Interconnect Technology [44] Group 10 - Jinyu Group's subsidiary acquired a real estate project for 3.364 billion yuan [46][47] - Kaiweite's major shareholder plans to reduce holdings by up to 3% of the company's shares [48] - Ningbo Energy's subsidiary plans to publicly transfer fixed assets valued at approximately 17.4372 million yuan [49]

Group 1: Industry Overview - In May, at least six domestic innovative pharmaceutical companies announced BD transaction orders, primarily involving cross-border collaborations between Chinese and foreign pharmaceutical companies [1] - The total amount of license-out transactions by Chinese innovative pharmaceutical companies reached $45.5 billion from January to May 2025, indicating a significant surge in outbound transactions compared to $51.9 billion for the entire year of 2024 [1] - The Chinese innovative drug market is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2] Group 2: Company Highlights - 3SBio and its subsidiary, 3SBio Guojian, entered into a global exclusive development rights agreement with Pfizer, featuring a $1.25 billion upfront payment and a potential total transaction value exceeding $6 billion, setting new records for Chinese innovative drugs [1] - Following the announcement, 3SBio's stock surged over 32%, with its subsidiary's stock hitting multiple daily limit-ups, effectively doubling in value [1] - CSPC Pharmaceutical Group is in discussions regarding three potential transactions related to drug development, production, and commercialization, with a total potential transaction value of approximately $5 billion, leading to a stock price increase of over 12% in a single day [1][2] Group 3: Market Performance - Innovative drug-related ETFs have shown strong performance, with year-to-date increases of 48.53%, 47.97%, and 47.23% for three major ETFs [2] - The ASCO annual meeting showcased a record number of 73 oral presentations from Chinese companies, highlighting the growing recognition of Chinese innovative drugs on the global stage [2][3] - The performance of various indices, such as the Xinhua Manufacturing Outbound 50 and Xinhua TMT Outbound 50, has been notably positive, with significant increases driven by supportive policies and industry benefits [3][4]

Core Points - The company announced a cash dividend of 0.09 yuan per share, totaling approximately 55.51 million yuan to be distributed to shareholders [1] - The profit distribution plan was approved at the annual general meeting held on April 15, 2025 [1] - The dividend will be distributed based on the total share capital of 616,785,793 shares [1] Distribution Details - The cash dividend will be paid to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [1] - The actual cash dividend received by individual shareholders may vary based on their holding period, with different tax implications for different durations [2][3][4] - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, while those holding for less than one year will have tax withheld upon transfer [2][3] Tax Implications - For individual shareholders holding shares for one month or less, a 20% personal income tax applies to the dividend income [3] - For those holding shares between one month and one year, a reduced tax rate of 10% applies [3] - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld, resulting in a net dividend of 0.081 yuan per share [4] Additional Information - The company will not withhold corporate income tax for other institutional investors, who are responsible for their own tax payments [5] - Shareholders with questions regarding the dividend distribution can contact the company's board office [5]

证券代码：688336 证券简称：三生国健 公告编号：2025-030 三生国健药业（上海）股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.09元（含税） 相关日期 二、 分配方案 1. 发放年度：2024年年度 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/12 | 2025/6/13 | 2025/6/13 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 15日的2024年年度股东大会 审议通过。 是否涉及差异化分红送转：否 每股分配比例 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结 算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本616,785,793股为基数， 每股派发现金红利0.09元（含税），共计派发现金红 ...

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The ASCO conference showcased significant breakthroughs in both foreign and domestic innovative drugs, highlighting the competitive strength of domestic companies [4][9] - A total of 73 research data entries from domestic companies were included in this year's ASCO, marking a historical high, with 32 being oral presentations and 11 classified as Late-Breaking Abstracts [9][13] - In the NSCLC (non-small cell lung cancer) sector, domestic research is leading globally, with promising data from dual antibodies and ADC (antibody-drug conjugates) [9][10] Summary by Sections Dual Antibodies - PD-1/VEGF dual antibodies are gaining attention, with significant transactions occurring in the market, indicating a heated competition [10][14] - SSGJ-707 from Sanofi has shown impressive efficacy in treating PD-L1 positive advanced NSCLC, with a clinical data showing a cORR of 64.7% and DCR of 97.1% in a specific dosage group [15][16] - PD-1/IL-2, a globally first dual-specific antibody, has demonstrated remarkable efficacy in late-stage NSCLC patients, with a 12-month OS rate of 71.6% [18][19] ADC (Antibody-Drug Conjugates) - ADC combined with immune checkpoint inhibitors is set to replace traditional chemotherapy, with domestic products expected to play a significant role [10][27] - The TROP2 ADC combined with PD-(L)1 has shown promising results in first-line treatment for advanced NSCLC, with an ORR of 55% [27][28] - Sac-TMT from Kelun Biotech has also shown superior efficacy in advanced NSCLC patients, particularly in those with high PD-L1 expression [30][31] Small Cell Lung Cancer (SCLC) - DLL3-targeted therapies have made significant progress, with domestic products demonstrating international competitiveness [10][39] - Tarlatamab has achieved breakthroughs in both second-line and first-line maintenance treatment for SCLC, expanding its indication [10][39] - Domestic DLL3 products have shown promising clinical data, indicating a strong potential for future development [10][39]